X

Trial Profile

An Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lumateperone (Primary)
Indications Schizophrenia
Focus Adverse reactions

Most Recent Events

10 May 2021 According to an Intra-Cellular Therapies media release, results from the study were presented at the American Psychiatric Association (APA) Annual Meeting 2021.
21 Jan 2021 According to an Intra-Cellular Therapies media release, results were recently published online in Schizophrenia Research.
21 Jan 2021 Results published in an Intra-Cellular Therapies media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com